Jiangsu Aidea Pharmaceutical Group Co., Ltd.SSE: 688488

Report for Q3 2025

Oct 31, 2025 · Issued by Jiangsu Aidea Pharmaceutical Group Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Oct 31, 2025

On 6ix: 6ix.com/news/report-for-q3-2025-629

Report for Q3 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Jiangsu Aidea Pharmaceutical Group Co., Ltd. on 6ix

Earlier from Jiangsu Aidea Pharmaceutical

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ADC118 TabletsOct 29, 2025
Announcement on Voluntary Disclosure of Marketing Authorization Approval Received for Dolutegravir Sodium Active Pharmaceutical IngredientOct 28, 2025
Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ADB116 for InjectionOct 25, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025Oct 16, 2025
Notice on Convening the 3rd Extraordinary General Meeting in 2025Sep 30, 2025

Later from Jiangsu Aidea Pharmaceutical

Announcement on Voluntary Disclosure of the Successful Enrollment of the 1st Subject in the Phase III Clinical Trial of ACC017 TabletsNov 8, 2025
Announcement on the Voluntary Disclosure of Renewal and Inclusion of Two Innovative Anti-HIV Drugs in the National Medical Insurance CatalogDec 8, 2025
Announcement on Estimated Amount of Daily Related Party Transactions in 2026Jan 1
Indicative Announcement on Disclosure of Plan for Issuing A-Shares to Specific Objects by Summary Procedures in 2026Jan 14
Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ADC205 TabletsJan 20

All Jiangsu Aidea Pharmaceutical news releases

Follow Jiangsu Aidea Pharmaceutical into a list and get an email when it puts out news.

Follow Jiangsu Aidea Pharmaceutical